MIRA INFORM REPORT

 

 

Report No. :

489128

Report Date :

06.02.2018

 

 

 

IDENTIFICATION DETAILS

 

Name :

AB SCIEX PTE. LTD.

 

 

Formerly Known As :

  • DH MANUFACTURING & DISTRIBUTION PTE. LTD.
  • DHR MANUFACTURING & DISTRIBUTION PTE. LTD.

 

 

Registered Office :

33, Marsiling Ind Estate Road 3, 04-06, 739256

 

 

Country :

Singapore

 

 

Financials (as on) :

31.12.2016

 

 

Date of Incorporation :

03.08.2009

 

 

Com. Reg. No.:

200914174C

 

 

Legal Form :

Private Limited (Limited By Share)

 

 

Line of Business :

Subject is engaged in the manufacturing of scientific equipment and other biological products.

 

 

No. of Employees :

450

 

 

 

 

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

 

MIRA’s Rating :

A

 

Credit Rating

Explanation

Rating Comments

A

Acceptable Risk

Business dealings permissible with moderate risk of default

 

Status :

Good

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List

 

Country Name

Previous Rating

(30.06.2017)

Current Rating

(30.09.2017)

Singapore

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low Risk

 

A2

Moderately Low Risk

 

B1

Moderate Risk

 

B2

Moderately High Risk

 

C1

High Risk

 

C2

Very High Risk

 

D

 


 

SINGAPORE - ECONOMIC OVERVIEW

 

Singapore has a highly developed and successful free-market economy. It enjoys a remarkably open and corruption-free environment, stable prices, and a per capita GDP higher than that of most developed countries. Unemployment is very low. The economy depends heavily on exports, particularly of consumer electronics, information technology products, medical and optical devices, pharmaceuticals, and on its vibrant transportation, business, and financial services sectors.

The economy contracted 0.6% in 2009 as a result of the global financial crisis, but has continued to grow since 2010. Growth in 2014-17 was slower than during the previous decade, at under 3% annually, largely a result of soft demand for exports amid a sluggish global economy and weak growth in Singapore’s manufacturing sector.

The government is attempting to restructure Singapore’s economy by weaning its dependence on foreign labor, addressing weak productivity growth, and increasing Singaporean wages. Singapore has attracted major investments in advanced manufacturing, pharmaceuticals, and medical technology production and will continue efforts to strengthen its position as Southeast Asia's leading financial and technology hub. Singapore is a member of the Regional Comprehensive Economic Partnership negotiations with the nine other ASEAN members plus Australia, China, India, Japan, South Korea, and New Zealand. In 2015, Singapore formed, with the other ASEAN members, the ASEAN Economic Community.

 

Source : CIA

 


EXECUTIVE SUMMARY

 

 

REGISTRATION NO.

:

200914174C

COMPANY NAME

:

AB SCIEX PTE. LTD.

FORMER NAME

:

DH MANUFACTURING & DISTRIBUTION PTE. LTD. (12/10/2009)
DHR MANUFACTURING & DISTRIBUTION PTE. LTD. (06/08/2009)

INCORPORATION DATE

:

03/08/2009

COMPANY STATUS

:

EXIST

LEGAL FORM

:

PRIVATE LIMITED (LIMITED BY SHARE)

LISTED STATUS

:

NO

REGISTERED ADDRESS

:

33, MARSILING IND ESTATE ROAD 3, 04-06, 739256, SINGAPORE.

BUSINESS ADDRESS

:

BLK 33, #04-06, MARSILING INDUSTRIAL ESTATE ROAD 3, 739256, SINGAPORE.

TEL.NO.

:

65-65861110/65594338

FAX.NO.

:

65-63623605

CONTACT PERSON

:

GORDON WILLIAM LOGAN ( DIRECTOR )

PRINCIPAL ACTIVITY

:

MANUFACTURING OF SCIENTIFIC EQUIPMENT AND OTHER BIOLOGICAL PRODUCTS

ISSUED AND PAID UP CAPITAL

:

266,276,933.00 ORDINARY SHARE, OF A VALUE OF USD 266,276,932.71

SALES

:

USD 417,694,311 [2016]

NET WORTH

:

USD 789,891,023 [2016]

STAFF STRENGTH

:

450 [2018]

BANKER (S)

:

HONGKONG & SHANGHAI BANKING CORPORATION LTD
BANK OF AMERICA N.A
CITIBANK SINGAPORE LIMITED

LITIGATION

:

CLEAR

FINANCIAL CONDITION

:

STRONG

PAYMENT

:

NO COMPLAINTS

MANAGEMENT CAPABILITY

:

AVERAGE

COMMERCIAL RISK

:

LOW

CURRENCY EXPOSURE

:

MODERATE

GENERAL REPUTATION

:

SATISFACTORY

INDUSTRY OUTLOOK

:

MARGINAL GROWTH

 

 

HISTORY / BACKGROUND

 

The Subject is a private limited company and is allowed to have a minimum of one and a maximum of forty-nine shareholders. As a private limited company, the Subject must have at least two directors. A private limited company is a separate legal entity from its shareholders. As a separate legal entity, the Subject is capable of owning assets, entering into contracts, sue or be sued by other companies. The liabilities of the shareholders are to the extent of the equity they have taken up and the creditors cannot claim on shareholders' personal assets even if the Subject is insolvent. The Subject is governed by the Companies Act and the company must file its annual returns, together with its financial statements with the Registrar of Companies.

The Subject is principally engaged in the (as a / as an) manufacturing of scientific equipment and other biological products.

 

The immediate holding company of the Subject is DHCDAN HOLDING APS, a company incorporated in DENMARK.

The ultimate holding company of the Subject is DANAHER CORPORATION, a company incorporated in UNITED STATES.

 

Share Capital History

Date

Issue & Paid Up Capital

05/02/2018

USD 266,276,932.71

 

The major shareholder(s) of the Subject are shown as follows :


Current Shareholder(s) :

Name

Address

IC/PP/Loc No

Shareholding

(%)

DHCDAN HOLDING APS

AKANDEVEJ 21, DK-2700, BRONSHOJ DENMARK

T11UF5098

266,276,933.00

100.00

---------------

------

266,276,933.00

100.00

============

=====

+ Also Director

 

The Subject's interest in other companies (Subsidiaries/Associates) are shown as follow :

 

Local No

Country

Company

Status

(%)

As At

53156237M

SINGAPORE

AB SCIEX (DISTRIBUTION)

-

100.00

05/02/2018

53156236X

SINGAPORE

AB SCIEX (MANUFACTURING)

-

100.00

05/02/2018

VIETNAM

DH VIETNAM COMPANY LIMITED

-

100.00

31/12/2016



DIRECTORS


DIRECTOR 1

 

Name Of Subject

:

MR. GORDON WILLIAM LOGAN

Address

:

5, ASPEN LEAF COURT, AURORA, ONTARIO, L4G 7T3, CANADA.

IC / PP No

:

761320731

Nationality

:

BRITISH

Date of Appointment

:

07/01/2013

 



INTEREST CHECK

Interest in companies

:

see below

Interest in business

:

none in our databank

Former interest

:

none in our databank

INTEREST IN COMPANY

No

Local No

Company

Designation

App Date

Shareholding

Profit/(loss) After Tax

Financial Year

Status

As At

No.

%

1

200914174C

AB SCIEX PTE. LTD.

Director

07/01/2013

0.00

-

USD60,291,972.00

2016

-

05/02/2018

 

DIRECTOR 2

 

Name Of Subject

:

TUEN POH YEAN

Address

:

220, LOYANG AVENUE, 03-02, LOYANG VALLEY, 509067, SINGAPORE.

IC / PP No

:

S2571866F

Nationality

:

SINGAPOREAN

Date of Appointment

:

05/02/2016



INTEREST CHECK

Interest in companies

:

see below

Interest in business

:

none in our databank

Former interest

:

none in our databank

INTEREST IN COMPANY

No

Local No

Company

Designation

App Date

Shareholding

Profit/(loss) After Tax

Financial Year

Status

As At

No.

%

1

200914174C

AB SCIEX PTE. LTD.

Director

05/02/2016

0.00

-

USD60,291,972.00

2016

-

05/02/2018

 

DIRECTOR 3

 

Name Of Subject

:

MC FADEN FRANK TALBOT

Address

:

2200, PENNSYLVANIA AVE., NW, SUITE 800W, WASHINGTON, DC, 20037, UNITED STATES.

IC / PP No

:

560996481

Nationality

:

AMERICAN

Date of Appointment

:

22/04/2014



INTEREST CHECK

Interest in companies

:

see below

Interest in business

:

none in our databank

Former interest

:

none in our databank

INTEREST IN COMPANY

No

Local No

Company

Designation

App Date

Shareholding

Profit/(loss) After Tax

Financial Year

Status

As At

No.

%

1

200914174C

AB SCIEX PTE. LTD.

Director

22/04/2014

0.00

-

USD60,291,972.00

2016

-

05/02/2018



MANAGEMENT

 

 

1)

Name of Subject

:

GORDON WILLIAM LOGAN

Position

:

DIRECTOR

 

 

AUDITOR

 

Auditor

:

ERNST & YOUNG LLP

Auditor' Address

:

N/A

 

 

COMPANY SECRETARIES

 

1)

Company Secretary

:

SIAU KUEI LIAN

IC / PP No

:

S7072715C

Address

:

224, SIMEI STREET 4, 11-114, 520224, SINGAPORE.

 

2)

Company Secretary

:

AZMAN HISHAM BIN JAAFAR

IC / PP No

:

S1699490A

Address

:

106, JALAN LANGGAR BEDOK, 468558, SINGAPORE.

 

BANKING


Banking relations are maintained principally with :

1)

Name

:

HONGKONG & SHANGHAI BANKING CORPORATION LTD

 

2)

Name

:

BANK OF AMERICA N.A

 

3)

Name

:

CITIBANK SINGAPORE LIMITED

 

 

 

ENCUMBRANCE (S)


No encumbrance was found in our databank at the time of investigation.

 

 

LITIGATION CHECK - SUBJECT COMPANY AS A DEFENDANT


* A check has been conducted in our databank against the Subject whether the subject has been involved in any litigation.

No legal action was found in our databank.

No winding up petition was found in our databank.

 

PAYMENT RECORD

 

 

SOURCES OF RAW MATERIALS:

Local

:

N/A

Overseas

:

N/A


The Subject refused to disclose its suppliers.

The Subject refused to provide any name of trade/service supplier and we are unable to conduct any trade enquiry. However, from financial historical data we conclude that :

OVERALL PAYMENT HABIT

Prompt 0-30 Days

[

]

Good 31-60 Days

[

]

Average 61-90 Days

[

X

]

Fair 91-120 Days

[

]

Poor >120 Days

[

]

 

 

CLIENTELE

 

Local

:

YES

Domestic Markets

:

SINGAPORE

Overseas

:

YES

Export Market

:

WORLDWIDE

Credit Term

:

30 DAYS

Payment Mode

:

CHEQUES
TELEGRAPHIC TRANSFER (TT)

 

 

OPERATIONS

 

Products manufactured

:

SCIENTIFIC EQUIPMENT AND OTHER BIOLOGICAL PRODUCTS

 

Total Number of Employees:

 

YEAR

2018

2016

2014


GROUP

N/A

N/A

N/A

COMPANY

450

30

30

 

Branch

:

NO

Other Information:


The Subject is principally engaged in the (as a / as an) manufacturing of scientific equipment and other biological products.

The Subject helps to improve the world we live in by enabling scientists and laboratory analysts to push the limits in their field and address the complex analytical challenges they face.

The Subject use high technology of machine in order to produce high quality of products.


CURRENT INVESTIGATION

 

Latest fresh investigations carried out on the Subject indicated that :

Telephone Number Provided By Client

:

N/A

Current Telephone Number

:

65-65861110/65594338

Match

:

N/A

Address Provided by Client

:

AB SCIEX, (DISTRIBUTION) DIVISION BLK 33, #04-06, MARSILING INDUSTRIAL SINGAPORE

Current Address

:

BLK 33, #04-06, MARSILING INDUSTRIAL ESTATE ROAD 3, 739256, SINGAPORE.

Match

:

NO


We have contacted the Subject's Accountant and its Company Secretary for the latest financial accounts. However they have rejected our request in view of the confidentiality of the documents.

 

Other Investigations


We have contacted one of the staff from the Subject and she provided some information.

The address provided is incomplete and as per stated in the report.

The Subject refused to disclose its number of employees.


FINANCIAL ANALYSIS

 

 

Profitability

Turnover

:

Increased

[

2012 - 2016

]

Profit/(Loss) Before Tax

:

Increased

[

2012 - 2016

]

Return on Shareholder Funds

:

Unfavourable

[

7.63%

]

Return on Net Assets

:

Unfavourable

[

7.90%

]

The Subject's turnover increased steadily as the demand for its products / services increased due to the goodwill built up over the years.The Subject's management have been efficient in controlling its operating costs. The unfavourable return on shareholders' funds could indicate that the Subject was inefficient in utilising its assets to generate returns.

Working Capital Control

Stock Ratio

:

Favourable

[

32 Days

]

Debtor Ratio

:

Favourable

[

16 Days

]

Creditors Ratio

:

Unfavourable

[

72 Days

]

The Subject's stocks were moving fast thus reducing its holding cost. This had reduced funds being tied up in stocks. The favourable debtors' days could be due to the good credit control measures implemented by the Subject. The unfavourable creditors' ratio could be due to the Subject taking advantage of the credit granted by its suppliers. However this may affect the goodwill between the Subject and its suppliers and the Subject may inadvertently have to pay more for its future supplies.

Liquidity

Liquid Ratio

:

Favourable

[

1.76 Times

]

Current Ratio

:

Unfavourable

[

1.91 Times

]

A minimum liquid ratio of 1 should be maintained by the Subject in order to assure its creditors of its ability to meet short term obligations and the Subject was in a good liquidity position. Thus, we believe the Subject is able to meet all its short term obligations as and when they fall due.

Solvency

Interest Cover

:

Nil

[

0.00 Times

]

Gearing Ratio

:

Favourable

[

0.00 Times

]

The Subject's interest cover was nil as it did not pay any interest during the year. The Subject had no gearing and hence it had virtually no financial risk. The Subject was financed by its shareholders' funds and internally generated fund. During the economic downturn, the Subject, having a zero gearing, will be able to compete better than those which are highly geared in the same industry.

Overall Assessment :

Generally, the Subject's performance has improved with higher turnover and profit. The Subject was in good liquidity position with its total current liabilities well covered by its total current assets. With its current net assets, the Subject should be able to repay its short term obligations. The Subject did not make any interest payment during the year. The Subject was dependent on its shareholders' funds to finance its business needs. The Subject was a zero gearing company, it was solely dependant on its shareholders to provide funds to finance its business. The Subject has good chance of getting loans, if the needs arises.

Overall financial condition of the Subject : STRONG

 

 

 

SINGAPORE ECONOMIC / INDUSTRY OUTLOOK

 

 

Major Economic Indicators :

2012

2013

2014

2015

2016*

 

Population (Million)

5.31

5.40

5.47

5.54

5.63

Gross Domestic Products ( % )

1.3

3.7

(3.5)

3.7

4.8

Consumer Price Index

4.6

2.4

2.4

(0.5)

(0.7)

Total Imports (Million)

474,554.0

466,762.0

463,779.1

407,767.9

398,372.0

Total Exports (Million)

510,329.0

513,391.0

518,922.7

476,285.4

468,552.0

 

Unemployment Rate (%)

2.0

1.9

1.9

1.9

2.1

Tourist Arrival (Million)

14.49

15.46

15.01

15.23

16.28

Hotel Occupancy Rate (%)

86.4

86.3

85.5

85.0

-

Cellular Phone Subscriber (Million)

1.52

1.97

1.98

1.99

-

 

Registration of New Companies (No.)

31,892

37,288

41,589

34,243

35,528

Registration of New Companies (%)

(1.3)

9.8

11.5

(17.7)

3.8

Liquidation of Companies (No.)

17,218

17,369

18,767

21,384

-

Liquidation of Companies (%)

9.4

(5.3)

8.0

13.9

-

 

Registration of New Businesses (No.)

24,788

22,893

35,773

28,480

33,326

Registration of New Businesses (%)

5.51

1.70

56.30

(20.39)

17.02

Liquidation of Businesses (No.)

22,489

22,598

22,098

26,116

-

Liquidation of Businesses (%)

(2.2)

0.5

(2.2)

18.2

-

 

Bankruptcy Orders (No.)

1,748

1,992

1,757

1,776

-

Bankruptcy Orders (%)

14.5

14.0

(11.8)

1.0

-

Bankruptcy Discharges (No.)

1,881

2,584

3,546

3,499

-

Bankruptcy Discharges (%)

35.2

37.4

37.2

(1.3)

-

 

INDUSTRIES ( % of Growth ) :

Agriculture

Production of Principal Crops

5.16

1.78

4.29

3.04

-

Fish Supply & Wholesale

(0.5)

(3.8)

(8.6)

(8.5)

(9.9)

 

Manufacturing #

Food, Beverages & Tobacco

97.9

97.9

99.4

100.0

103.7

Textiles

140.1

119.5

102.7

100.0

93.3

Wearing Apparel

395.4

334.1

212.6

100.0

80.3

Leather Products & Footwear

109.5

122.0

106.5

100.0

93.2

Wood & Wood Products

93.3

103.0

107.2

100.0

90.5

Paper & Paper Products

98.5

104.4

104.5

100.0

99.7

Printing & Media

122.8

113.8

105.968

100.0

86.9

Crude Oil Refineries

107.1

100.7

92.2

100.0

100.5

Chemical & Chemical Products

85.3

88.4

96.7

100.0

97.6

Pharmaceutical Products

103.8

101.421

109.4

100.0

115.9

Rubber & Plastic Products

113.5

109.497

109.2

100.0

87.9

Non-metallic Mineral

108.8

107.4

90.759

100.0

93.6

Basic Metals

91.5

77.2

99.3

100.0

113.1

Fabricated Metal Products

107.314

107.5

107.757

100.0

91.7

Machinery & Equipment

107.3

109.1

118.2

100.0

79.3

Electrical Machinery

80.102

87.4

97.871

100.0

99.3

Electronic Components

100.7

105.0

105.6

100.0

106.3

Transport Equipment

109.9

111.1

106.68

100.0

98.7

 

Construction

28.70

25.40

22.00

-

-

Real Estate

31.9

88.5

145.1

-

-

 

Services

Electricity, Gas & Water

6.30

6.70

6.50

-

-

Transport, Storage & Communication

5.30

9.80

14.20

-

-

Finance & Insurance

0.50

3.30

6.00

-

7.40

Government Services

6.00

6.50

6.30

-

-

Education Services

0.30

3.10

5.98

-

2.40

 

* Estimate / Preliminary

# Based on Index of Industrial Production (2015 = 100)



INDUSTRY ANALYSIS

 

INDUSTRY :

MANUFACTURING

In the first quarter of 2017, manufacturing output rose by 8.0%, following the increase of 11% in the previous quarter. The robust performance of the sector was underpinned by sustained growth in the electronics, precision engineering and chemicals clusters. For the whole year of 2016, the manufacturing sector grew by 3.6%, a reversal from the 5.1% contraction in the previous year.

The electronics cluster increased by 33% in the first quarter, largely driven by the semiconductors segment, which saw its output surge by 50%. The strong performance of the semiconductors segment can be attributed to the continued recovery in global semiconductors demand, driven in turn by healthy demand in key end markets such as smartphone and automotive applications. At the same time, the other electronic modules & components and computer peripherals segments grew by 9.0% and 1.2% respectively. For the full year of 2016, the electronics cluster expanded by 16%.

Besides, biomedical manufacturing cluster contracted by 7.5% in the first quarter of 2017. Within the cluster, the medical technology segment recorded robust growth of 14%, supported by higher export demand for medical instruments. However, this was outweighed by a 14% decline in the output of the pharmaceuticals segment as the production of active pharmaceutical ingredients fell. For 2016 as a whole, the biomedical manufacturing cluster expanded by 14%, with both the pharmaceuticals and medical technology segments supporting growth.

In the first quarter of 2017, output of the transport engineering cluster fell by 11%, dragged down by the marine & offshore engineering (M&OE) segment. This more than offset expansions in the aerospace (10%) and land (7.0%) segments. The aerospace segment, in particular, was supported by an increase in demand for aircraft and engine maintenance work. For the whole year of 2016, the transport engineering cluster contracted by 18%.

The precision engineering cluster expanded by 19% in the first quarter of 2017, supported by both the machinery & systems (M&S) and precision modules & components (PMC) segments. Output in the M&S segment rose by 24 % on the back of robust export demand for semiconductor manufacturing equipment. Meanwhile, the PMC segment grew by 11% due to an increase in the production of dies, moulds, tools, jigs & fixtures, optical instruments and metal precision components. In 2016, the precision engineering cluster’s output rose by 0.8%.

Moreover, output of the general manufacturing industries shrank by 6.7% in the first quarter 2017. In particular, the output of the miscellaneous industries segment fell by 12% due to a decline in the production of fibre glass products and construction-related products & materials. The printing segment contracted by 21%, as demand for commercial printing remained weak and the food, beverage & tobacco segment expanded by 3.2%, supported by healthy export demand. For the full year 2016, the general manufacturing industries contracted by 2.5%.

The output of the chemicals cluster increased by 2.9% in the first quarter of 2017 supported primarily by growth in the petrochemicals (9.8%) and specialty chemicals (2.9%) segments. Growth in the petrochemicals segment was partly the result of a low base effect as production levels a year ago were weak due to plant maintenance shutdowns. On the other hand, the other chemicals segment contracted to 5.6% on account of a lower level of production of fragrances. For the full year 2016, the chemicals cluster contracted by 0.9 per cent. This was due to a decline in the output of the petrochemicals segment arising from major plant maintenance shutdowns, even as the output of all other segments expanded.

OVERALL INDUSTRY OUTLOOK : MARGINAL GROWTH



CREDIT RISK EVALUATION & RECOMMENDATION

 


Incorporated in 2009, the Subject is a Private Limited company, focusing on manufacturing of scientific equipment and other biological products. Having been in business for more than 5 years, the Subject has established a remarkable clientele base for itself which has contributed to its business growth. Presently, the issued and paid up capital of the Subject stands at USD 266,276,933.


Investigation revealed, the Subject has penetrated into both the local and overseas market. The Subject has positioned itself in the global market and is competing in the industry. Its stable clientele base will enable the Subject to further enhance its business in the near term. The Subject is a fairly large and rapidly growing company with over 450 staff in its operations Overall, we regard that the Subject's management capability is average. This indicates that the Subject has greater potential to improve its business performance and raising income for the Subject.

 
We noted that both the turnover and profits have increased compared to the previous year. The higher profit could be due to increase in turnover and better control over its operating costs. The Subject has generated an unfavourable return on shareholders' funds indicating that the management was inefficient in utilising its funds to generate return. The Subject is in good liquidity position with its current liabilities well covered by it current assets. Hence, it has sufficient working capital to meet its short term financial obligations. Being a zero geared company, the Subject virtually has no financial risk as it is mainly dependent on its internal funds to finance its business. Given a positive net worth standing at USD 789,891,023, the Subject should be able to maintain its business in the near terms.

 
The Subject's payment habit is average. With its adequate working capital, the Subject should be able to pay its short term debts.


The industry has reached its maturity stage and only enjoying a marginal growth. The steady growth of the country's economy will further enhance the industry activities. Thus, the Subject's future performance is very much depend on its marketing strategies in order to retain its position in the market.

 
Based on the above condition, we recommend credit be granted to the Subject normally.



PROFIT AND LOSS ACCOUNT

 

 

THE FINANCIAL STATEMENTS WERE PREPARED IN ACCORDANCE WITH SINGAPORE FINANCIAL REPORTING STANDARDS.

AB SCIEX PTE. LTD.

 

Financial Year End

2016-12-31

2015-12-31

2014-12-31

2013-12-31

2012-12-31

Months

12

12

12

12

12

Consolidated Account

Company

Company

Company

Company

Company

Audited Account

YES

YES

YES

YES

YES

Unqualified Auditor's Report (Clean Opinion)

YES

YES

YES

YES

YES

Financial Type

FULL

FULL

FULL

FULL

FULL

Currency

USD

USD

USD

USD

USD

TURNOVER

417,694,311

401,650,233

396,184,826

390,534,651

353,839,356

----------------

----------------

----------------

----------------

----------------

Total Turnover

417,694,311

401,650,233

396,184,826

390,534,651

353,839,356

Costs of Goods Sold

(209,343,903)

(202,304,251)

(190,198,096)

(178,877,234)

(148,985,518)

----------------

----------------

----------------

----------------

----------------

Gross Profit

208,350,408

199,345,982

205,986,730

211,657,417

204,853,838

----------------

----------------

----------------

----------------

----------------

PROFIT/(LOSS) FROM OPERATIONS

62,365,416

57,409,112

105,724,048

111,792,099

68,328,716

----------------

----------------

----------------

----------------

----------------

PROFIT/(LOSS) BEFORE TAXATION

62,365,416

57,409,112

105,724,048

111,792,099

68,328,716

Taxation

(2,073,444)

(566,312)

(571,473)

(367,662)

(99,000)

----------------

----------------

----------------

----------------

----------------

PROFIT/(LOSS) AFTER TAXATION

60,291,972

56,842,800

105,152,575

111,424,437

68,229,716

----------------

----------------

----------------

----------------

----------------

RETAINED PROFIT/(LOSS) BROUGHT FORWARD

As previously reported

463,322,119

406,479,319

301,326,744

189,902,307

121,672,591

----------------

----------------

----------------

----------------

----------------

As restated

463,322,119

406,479,319

301,326,744

189,902,307

121,672,591

----------------

----------------

----------------

----------------

----------------

PROFIT AVAILABLE FOR APPROPRIATIONS

523,614,091

463,322,119

406,479,319

301,326,744

189,902,307

----------------

----------------

----------------

----------------

----------------

RETAINED PROFIT/(LOSS) CARRIED FORWARD

523,614,091

463,322,119

406,479,319

301,326,744

189,902,307

=============

=============

=============

=============

=============

INTEREST EXPENSE (as per notes to P&L)

Others

-

-

443,070

702,625

509,512

----------------

----------------

----------------

----------------

----------------

-

-

443,070

702,625

509,512

=============

=============

=============

=============

=============

DEPRECIATION (as per notes to P&L)

2,581,280

1,215,019

2,940,796

2,367,406

2,865,105

AMORTIZATION

5,445,962

5,445,962

5,445,962

5,445,961

5,445,962

----------------

----------------

----------------

----------------

----------------

Total Amortization And Depreciation

8,027,242

6,660,981

8,386,758

7,813,367

8,311,067

=============

=============

=============

=============

=============

 

 

 

 

 

 

 

 

BALANCE SHEET

 

 

AB SCIEX PTE. LTD.

 

ASSETS EMPLOYED:

FIXED ASSETS

3,922,291

3,787,009

5,114,941

6,424,762

5,496,402

LONG TERM INVESTMENTS/OTHER ASSETS

Subsidiary companies

70,000

70,000

70,000

70,000

70,000

Investments

384,875,316

358,593,721

374,796,856

160,000,000

160,000,000

----------------

----------------

----------------

----------------

----------------

TOTAL LONG TERM INVESTMENTS/OTHER ASSETS

384,945,316

358,663,721

374,866,856

160,070,000

160,070,000

INTANGIBLE ASSETS

Own goodwill

32,301,164

32,301,164

32,301,164

32,301,164

32,301,164

Trademarks

142,654,300

142,654,300

142,654,300

142,654,300

142,654,300

Others

38,121,735

43,567,697

49,013,659

54,459,621

59,905,582

----------------

----------------

----------------

----------------

----------------

TOTAL INTANGIBLE ASSETS

213,077,199

218,523,161

223,969,123

229,415,085

234,861,046

----------------

----------------

----------------

----------------

----------------

TOTAL LONG TERM ASSETS

601,944,806

580,973,891

603,950,920

395,909,847

400,427,448

CURRENT ASSETS

Stocks

30,854,081

29,077,620

32,950,632

25,849,480

24,352,863

Contract work-in-progress

5,628,277

3,875,006

3,943,570

2,890,382

2,658,592

Trade debtors

18,116,861

26,442,215

27,724,696

19,355,632

13,181,683

Other debtors, deposits & prepayments

8,287,133

8,529,598

8,867,809

28,645,880

61,392,179

Amount due from holding company

80,882,950

44,743,630

100,119,286

205,040,602

98,674,777

Amount due from related companies

249,926,081

243,378,229

52,555,621

78,375,300

55,209,311

Cash & bank balances

230,434

445,737

1,168,402

612,985

3,013

----------------

----------------

----------------

----------------

----------------

TOTAL CURRENT ASSETS

393,925,817

356,492,035

227,330,016

360,770,261

255,472,418

----------------

----------------

----------------

----------------

----------------

TOTAL ASSET

995,870,623

937,465,926

831,280,936

756,680,108

655,899,866

=============

=============

=============

=============

=============

CURRENT LIABILITIES

Trade creditors

41,237,539

41,695,374

48,106,979

38,372,348

19,694,448

Other creditors & accruals

21,064,911

9,186,427

5,131,328

6,924,339

16,759,665

Bank overdraft

1,054,472

-

-

-

321,759

Deposits from customers

11,160,929

926,060

46,925

1,287,628

1,150,512

Amounts owing to related companies

129,015,589

154,191,166

103,561,248

141,507,680

160,559,491

Provision for taxation

1,368,346

639,773

526,683

-

-

Other liabilities

1,077,814

1,228,075

1,151,522

984,437

1,234,752

----------------

----------------

----------------

----------------

----------------

TOTAL CURRENT LIABILITIES

205,979,600

207,866,875

158,524,685

189,076,432

199,720,627

----------------

----------------

----------------

----------------

----------------

NET CURRENT ASSETS/(LIABILITIES)

187,946,217

148,625,160

68,805,331

171,693,829

55,751,791

----------------

----------------

----------------

----------------

----------------

TOTAL NET ASSETS

789,891,023

729,599,051

672,756,251

567,603,676

456,179,239

=============

=============

=============

=============

=============

FINANCED BY:

SHARE CAPITAL

Ordinary share capital

266,276,932

266,276,932

266,276,932

266,276,932

266,276,932

----------------

----------------

----------------

----------------

----------------

TOTAL SHARE CAPITAL

266,276,932

266,276,932

266,276,932

266,276,932

266,276,932

RESERVES

Retained profit/(loss) carried forward

523,614,091

463,322,119

406,479,319

301,326,744

189,902,307

----------------

----------------

----------------

----------------

----------------

TOTAL RESERVES

523,614,091

463,322,119

406,479,319

301,326,744

189,902,307

----------------

----------------

----------------

----------------

----------------

SHAREHOLDERS' FUNDS/EQUITY

789,891,023

729,599,051

672,756,251

567,603,676

456,179,239

=============

=============

=============

=============

=============

 

 

 

 

 

 

 

 

FINANCIAL RATIO

 

 

AB SCIEX PTE. LTD.

 

TYPES OF FUNDS

Cash

230,434

445,737

1,168,402

612,985

3,013

Net Liquid Funds

(824,038)

445,737

1,168,402

612,985

(318,746)

Net Liquid Assets

157,092,136

119,547,540

35,854,699

145,844,349

31,398,928

Net Current Assets/(Liabilities)

187,946,217

148,625,160

68,805,331

171,693,829

55,751,791

Net Tangible Assets

576,813,824

511,075,890

448,787,128

338,188,591

221,318,193

Net Monetary Assets

157,092,136

119,547,540

35,854,699

145,844,349

31,398,928

PROFIT & LOSS ITEMS

Earnings Before Interest & Tax (EBIT)

62,365,416

57,409,112

106,167,118

112,494,724

68,838,228

Earnings Before Interest, Taxes, Depreciation And Amortization (EBITDA)

70,392,658

64,070,093

114,553,876

120,308,091

77,149,295

BALANCE SHEET ITEMS

Total Borrowings

1,054,472

0

0

0

321,759

Total Liabilities

205,979,600

207,866,875

158,524,685

189,076,432

199,720,627

Total Assets

995,870,623

937,465,926

831,280,936

756,680,108

655,899,866

Net Assets

789,891,023

729,599,051

672,756,251

567,603,676

456,179,239

Net Assets Backing

789,891,023

729,599,051

672,756,251

567,603,676

456,179,239

Shareholders' Funds

789,891,023

729,599,051

672,756,251

567,603,676

456,179,239

Total Share Capital

266,276,932

266,276,932

266,276,932

266,276,932

266,276,932

Total Reserves

523,614,091

463,322,119

406,479,319

301,326,744

189,902,307

GROWTH RATIOS (Year on Year) (%)

Revenue

3.99

1.38

1.45

10.37

-

Proft/(Loss) Before Tax

8.63

(45.70)

(5.43)

63.61

-

Proft/(Loss) After Tax

6.07

(45.94)

(5.63)

63.31

-

Total Assets

6.23

12.77

9.86

15.37

-

Total Liabilities

(0.91)

31.13

(16.16)

(5.33)

-

LIQUIDITY (Times)

Cash Ratio

0

0

0.01

0

0

Liquid Ratio

1.76

1.58

1.23

1.77

1.16

Current Ratio

1.91

1.72

1.43

1.91

1.28

WORKING CAPITAL CONTROL (Days)

Stock Ratio

32

30

34

27

28

Debtors Ratio

16

24

26

18

14

Creditors Ratio

72

75

92

78

48

SOLVENCY RATIOS (Times)

Gearing Ratio

0

0

0

0

0

Liabilities Ratio

0.26

0.28

0.24

0.33

0.44

Times Interest Earned Ratio

0

0

239.62

160.11

135.11

Assets Backing Ratio

2.17

1.92

1.69

1.27

0.83

PERFORMANCE RATIO (%)

Operating Profit Margin

14.93

14.29

26.69

28.63

19.31

Net Profit Margin

14.43

14.15

26.54

28.53

19.28

Return On Net Assets

7.90

7.87

15.78

19.82

15.09

Return On Capital Employed

6.21

6.06

11.84

14.11

9.96

Return On Shareholders' Funds/Equity

7.63

7.79

15.63

19.63

14.96

Dividend Pay Out Ratio (Times)

0

0

0

0

0

NOTES TO ACCOUNTS

Contingent Liabilities

0

0

0

0

0


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

INR 64.03

UK Pound

1

INR 90.40

Euro

1

INR 79.73

SGD

1

INR 48.63

 

Note : Above are approximate rates obtained from sources believed to be correct

 

 

INFORMATION DETAILS

 

Analysis Done by :

VIV

 

 

Report Prepared by :

TRU

 


 

RATING EXPLANATIONS

 

Credit Rating

Explanation

Rating Comments

A++

Minimum Risk

Business dealings permissible with minimum risk of default

A+

Low Risk

Business dealings permissible with low risk of default

A

Acceptable Risk

Business dealings permissible with moderate risk of default

B

Medium Risk

Business dealings permissible on a regular monitoring basis

C

Medium High Risk

Business dealings permissible preferably on secured basis

D

High Risk

Business dealing not recommended or on secured terms only

NB

New Business

No recommendation can be done due to business in infancy stage

NT

No Trace

No recommendation can be done as the business is not traceable

 

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

 

·         Financial condition covering various ratios

·         Company background and operations size

·         Promoters / Management background

·         Payment record

·         Litigation against the subject

·         Industry scenario / competitor analysis

·         Supplier / Customer / Banker review (wherever available)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.